With the rapid development of biotechnology, immunology research has gradually penetrated into the cellular and molecular level. In this context, the iHuPBMC-T platform launched by InnoModels Biotechnology is becoming an important tool in the field of immunology research by virtue of its unique technical features and application value.
1、Advanced MHC knockdown technology
MHC (major histocompatibility complex) genes play a crucial role in the immune system and are closely related to the processes of immune response, immune recognition and immune regulation. However, the high degree of polymorphism in MHC genes poses a great challenge to immunological research. The iHuPBMC-T platform of InnoModels Biotechnology has successfully realized the knockdown of MHC gene by using advanced gene editing technology. This technological breakthrough provides a new perspective for immunological research, enabling researchers to explore the function and mechanism of the immune system more deeply under the condition of MHC deletion.

2. Revealing the mechanism of immune tolerance and rejection
The mechanism of immune tolerance and rejection is one of the core contents of immunological research. Through MHC knockdown, the iHuPBMC-T platform provides an ideal experimental tool for studying the mechanisms of immune tolerance and rejection. With the help of this platform, researchers can simulate the immune response process under different MHC genotypes, revealing how the immune system recognizes and handles its own tissues, foreign antigens and other complex issues. This research not only helps to understand the basic principles of the immune system, but also provides new therapeutic strategies for organ transplantation and autoimmune diseases.
3、Promote the development of personalized immunotherapy
With the rise of precision medicine, personalized immunotherapy has become a research hotspot in the field of immunotherapy. The iHuPBMC-T platform of InnoModels Biotechnology provides strong support for the development of personalized immunotherapy by simulating the immune response under different MHC genotypes. With the help of this platform, researchers can design more accurate and effective immunotherapy programs for specific individuals' immune system characteristics. This will not only improve therapeutic efficacy and reduce side effects, but also bring benefits to more patients with immunomodulatory diseases.
In conclusion, the iHuPBMC-T platform of InnoModels Biotechnology is becoming an important tool in the field of immunology research by virtue of its advanced MHC knockdown technology, its unique features in revealing the mechanisms of immune tolerance and rejection, and its ability to drive the development of personalized immunotherapies. In the future, with the continuous improvement of the platform's technology and the expansion of its application areas, we believe that it will play an even more important role in the field of immunotherapy and make greater contributions to human health.